Expected Moves

H1 2026 results combined with the anticipated strategic roadmap from new CEO Stéphane Ledermann. Favorable reception targets $0.95, while disappointment risks a drop to $0.55 from the $0.69 base price.

Anticipated regulatory clearance to resume the Phase 3 AB23005 trial in ALS. Approval to proceed supports a rally to $1.20, whereas continued clinical holds would collapse the price to $0.70 from the $0.95 base.

Expected health authority authorization to initiate the triple-combination Phase 4 study for AB8939 in AML. A green light pushes shares to $1.50, while rejection or safety holds force a retreat to $0.85 from the $1.20 anchor.

Full year 2026 earnings release where cash burn from pivotal trials will take center stage. From a $1.50 base, an adverse realization of depleted cash targets a drop to $1.05, while unexpected non-dilutive funding could push shares to $1.75.

Projection of a necessary capital raise to fund ongoing operations. The base case anticipates a discounted equity offering dropping shares from $1.05 to $0.65, whereas a strategic partnership could re-rate the stock to $1.30.